- Home
- FTDR vs SWTX Comparison
FTDR vs SWTX Comparison
Compare FTDR & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- SWTX
- Stock Information
- Founded
- FTDR 1971
- SWTX 2017
- Country
- FTDR United States
- SWTX United States
- Employees
- FTDR N/A
- SWTX N/A
- Industry
- FTDR Diversified Commercial Services
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- FTDR Finance
- SWTX Health Care
- Exchange
- FTDR Nasdaq
- SWTX Nasdaq
- Market Cap
- FTDR 3.6B
- SWTX 3.0B
- IPO Year
- FTDR 2018
- SWTX 2019
- Fundamental
- Price
- FTDR $57.10
- SWTX $58.25
- Analyst Decision
- FTDR Hold
- SWTX Strong Buy
- Analyst Count
- FTDR 6
- SWTX 6
- Target Price
- FTDR $48.60
- SWTX $70.83
- AVG Volume (30 Days)
- FTDR 581.7K
- SWTX 3.2M
- Earning Date
- FTDR 02-27-2025
- SWTX 02-20-2025
- Dividend Yield
- FTDR N/A
- SWTX N/A
- EPS Growth
- FTDR 42.94
- SWTX N/A
- EPS
- FTDR 3.00
- SWTX N/A
- Revenue
- FTDR $1,827,000,000.00
- SWTX $191,589,000.00
- Revenue This Year
- FTDR $4.78
- SWTX $3,475.18
- Revenue Next Year
- FTDR $6.38
- SWTX $81.60
- P/E Ratio
- FTDR $19.44
- SWTX N/A
- Revenue Growth
- FTDR 4.16
- SWTX 3417.33
- 52 Week Low
- FTDR $29.41
- SWTX $28.21
- 52 Week High
- FTDR $63.49
- SWTX $62.00
- Technical
- Relative Strength Index (RSI)
- FTDR 43.77
- SWTX 70.71
- Support Level
- FTDR $56.43
- SWTX $54.89
- Resistance Level
- FTDR $60.19
- SWTX $62.00
- Average True Range (ATR)
- FTDR 1.54
- SWTX 4.09
- MACD
- FTDR -0.30
- SWTX 1.35
- Stochastic Oscillator
- FTDR 12.86
- SWTX 85.90
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.